Hiteck(SZ:300683)2026-01-23 12:22Financial Projections - The company expects a net profit loss of between 17,000 and 24,000 million yuan for the year 2025, compared to a loss of 6,934.87 million yuan in 2024[4] - Total profit is projected to be a loss of between 18,000 and 26,000 million yuan, up from a loss of 8,014.06 million yuan in the previous year[4] - Operating revenue is estimated to be between 48,210 and 58,659 million yuan, a decrease from 64,897.41 million yuan in 2024[4] Impairment Losses - The company plans to recognize an impairment loss of approximately 8,500 million yuan on goodwill related to its subsidiary Tianjin Hankan Pharmaceutical Technology Co., Ltd due to expected revenue decline[7] - Inventory impairment losses of about 11.93 million yuan are expected due to increased market competition and insufficient orders in the raw materials and intermediates business[7] Non-Recurring Gains and Losses - The company anticipates a significant impact on net profit from non-recurring gains and losses, estimated between 28 million and 36 million yuan, primarily from investment income and government subsidies[7] Financial Data and Forecast - The company has communicated with its accounting firm regarding the earnings forecast, and there are no disagreements on the forecast[5] - The financial data presented is preliminary and has not been audited by the accounting firm, with the final figures to be disclosed in the 2025 annual report[8] - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the financial data[8] Market Risks - The company is facing risks from market competition and policy adjustments that may affect its revenue and profitability[6]